ArticleOncoTargets and therapy2020
Acute Myeloid Leukemia with
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Review
- Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia.Current oncology reports · 2025Review
- Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.International journal of hematology · 2025Review
- Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia.Nature communications · 2025Article
- CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia.Nature communications · 2025Article
- Identification and visualization of fusion gene subtypes in APL using spatial attention mechanisms in vision models.Frontiers in oncology · 2025Article
- Review
- Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.Annals of hematology · 2024Review
- Article
- A global study for acute myeloid leukemia with RARG rearrangement.Blood advances · 2023Article
- Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia withTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- [Advances in the recognition of acute myeloid leukemia with RARG-rearrangement].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.Frontiers in oncology · 2022Review
- Comment on Geoffroy, M.-C.; de Thé, H. Classic and Variants APLs, as Viewed from a Therapy Response.Cancers · 2021Article
- Current views on the genetic landscape and management of variant acute promyelocytic leukemia.Biomarker research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoic acid receptor gamma (RARG) belongs to the nuclear receptor superfamily and has 90% homology to RAR alpha (RARA) and RAR beta. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.